Alkem Lab

Why is Alkem Laboratories Ltd falling/rising?

As of 27-Aug, Alkem Laboratories Ltd's stock price is at 5,314.35, reflecting a decline of 0.48%. The stock has been on a downward trend, underperforming its sector and trading below key moving averages, indicating bearish conditions and reduced investor interest.

As of 27-Aug, Alkem Laboratories Ltd's stock price is falling, currently at 5,314.35, which reflects a decrease of 25.85 (-0.48%). The stock has been on a downward trend, having lost 1.59% over the past week and 5.34% over the past month. This decline is compounded by the fact that the stock has been losing for the last five consecutive days. <BR><BR>Additionally, the stock is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. The performance today shows that it underperformed its sector by 1.2%, and it is currently 4.32% away from its 52-week low. <BR><BR>Investor participation has also decreased, with delivery volume dropping by 66.15% compared to the 5-day average. Despite the company's high management efficiency and being net-debt free, these negative indicators contribute to the stock's current decline. Overall, the combination of poor short-term performance, reduced investor interest, and trading below key moving averages suggests that Alkem Laboratories Ltd's stock is experiencing a downward movement.

Which are the latest news on Alkem Lab?

Should I buy, sell or hold Alkem Laboratories Ltd?

Who are in the management team of Alkem Lab?

The management team of Alkem Lab includes Executive Chairman Basudeo N Singh, Managing Director Sandeep Singh, and several Executive Directors, along with Non-Executive and Independent Directors such as A K Purwar and Sangeeta Kapiljit Singh, totaling a diverse group that guides the company's operations and strategy. Manish Narang serves as the Company Secretary and Compliance Officer.

The management team of Alkem Lab includes the following key members:<BR><BR>1. **Basudeo N Singh** - Executive Chairman<BR>2. **Sandeep Singh** - Managing Director<BR>3. **Mritunjay Kumar Singh** - Executive Director<BR>4. **Sarvesh Singh** - Executive Director<BR>5. **Madhurima Singh** - Executive Director<BR>6. **Srinivas Singh** - Executive Director<BR>7. **A K Purwar** - Non-Executive & Independent Director<BR>8. **Sangeeta Kapiljit Singh** - Non-Executive & Independent Director<BR>9. **Sudha Ravi** - Non-Executive & Independent Director<BR>10. **Dheeraj Sharma** - Non-Executive & Independent Director<BR>11. **Narendra Aneja** - Non-Executive & Independent Director<BR>12. **Sujjain Talwar** - Independent Director<BR>13. **Manish Narang** - Company Secretary & Compliance Officer<BR><BR>This diverse team brings a wealth of experience and expertise to the company, supporting its operations and strategic direction.

What does Alkem Lab do?

Alkem Laboratories Ltd is a prominent Indian pharmaceutical company founded in 1973, specializing in the development, manufacture, and sale of pharmaceutical and nutraceutical products. As of March 2026, it reported net sales of ₹3,603 Cr and a net profit of ₹236 Cr, with a market cap of ₹64,948 Cr.

Overview:<BR>Alkem Laboratories Ltd is a leading Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Mid Cap.<BR><BR>History:<BR>Alkem Laboratories Ltd was incorporated in the year 1973. The latest quarterly results reported are for March 2026, showcasing the company's performance in terms of sales and profit.<BR><BR>Financial Snapshot:<BR>- Net Sales: 3,603 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 236 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 64,948 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 27.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.97%<BR>- Debt Equity: -0.03<BR>- Return on Equity: 17.48%<BR>- Price to Book: 4.73<BR><BR>Contact Details:<BR>Address: Alkem House Senapati Bapat Marg, Lower Parel Mumbai Maharashtra : 400013<BR>Tel: 91-22-39829999<BR>Email: investors@alkem.com<BR>Website: http://www.alkemlabs.com

Who are the peers of the Alkem Lab?

Alkem Lab's peers include Mankind Pharma, Laurus Labs, Dr Reddy's Labs, Aurobindo Pharma, Biocon, Glenmark Pharma, Abbott India, Anthem Bioscienc, Gland Pharma, and Ipca Labs. In terms of management risk, growth, and capital structure, Alkem Lab is rated as good, with a 1-year return of 0.52%.

Peers: The peers of Alkem Lab are Mankind Pharma, Laurus Labs, Dr Reddy's Labs, Aurobindo Pharma, Biocon, Glenmark Pharma, Abbott India, Anthem Bioscienc, Gland Pharma, and Ipca Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Abbott India, Anthem Bioscienc, and Glenmark Pharma, while Good management risk is found at Mankind Pharma, Dr Reddy's Labs, Alkem Lab, and the rest. Average management risk is noted at Aurobindo Pharma and Biocon, while the rest have Below Average management risk. For Growth, Excellent growth is seen at Anthem Bioscienc, while Good growth is observed at Mankind Pharma and Glenmark Pharma. Average growth is found at Dr Reddy's Labs and Biocon, while Below Average growth is noted at Alkem Lab, Laurus Labs, Aurobindo Pharma, Gland Pharma, and the rest. In terms of Capital Structure, Excellent capital structure is seen at Mankind Pharma, Dr Reddy's Labs, Aurobindo Pharma, Alkem Lab, Gland Pharma, and the rest, while Average capital structure is noted at Laurus Labs, and Below Average at Biocon.<BR><BR>Return Snapshot: Laurus Labs has the highest 1-year return at 113.22%, while Abbott India has the lowest at -16.28%. Alkem Lab's 1-year return is 0.52%, which is higher than Abbott India's but lower than Laurus Labs'. Additionally, the peers with negative six-month returns include Dr Reddy's Labs and Biocon.

How big is Alkem Lab?

As of 14th August, Alkem Laboratories Ltd has a market capitalization of 63,932.60 Cr, with recent net sales of 14,712.27 Cr and net profit of 2,301.80 Cr over the last four quarters.

As of 14th August, <BR><BR>Market Cap: Alkem Laboratories Ltd has a market capitalization of 63,932.60 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 14,712.27 Cr, while the sum of Net Profit for the same period is 2,301.80 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2026, with Shareholder's Funds amounting to 13,820.10 Cr and Total Assets valued at 19,053.62 Cr.

Are Alkem Laboratories Ltd latest results good or bad?

Alkem Laboratories Ltd's latest Q4 FY26 results are concerning, showing a 14.62% revenue growth but a significant 62.82% decline in net profit quarter-on-quarter, indicating operational challenges and margin compression. Overall, the results are considered bad, highlighting the need for improved cost management and efficiency.

Alkem Laboratories Ltd's latest results for Q4 FY26 indicate a challenging financial situation. While the company achieved a year-on-year revenue growth of 14.62%, reaching net sales of ₹3,603.32 crores, its consolidated net profit saw a significant decline of 62.82% quarter-on-quarter and 22.69% year-on-year, dropping to ₹236.46 crores. <BR><BR>This sharp profit decline is concerning, especially given the revenue growth, suggesting issues with cost management and operational efficiency. The operating margin, which fell to 14.36% from 22.16% in the previous quarter, reflects severe margin compression. Additionally, the profit after tax (PAT) margin decreased dramatically to 6.98%, raising questions about the sustainability of the company's profitability.<BR><BR>Overall, the results can be characterized as bad, highlighting operational distress and significant challenges that need to be addressed for future stability and growth.

When is the next results date for Alkem Laboratories Ltd?

The next results date for Alkem Laboratories Ltd is 28 May 2026.

The next results date for Alkem Laboratories Ltd is scheduled for 28 May 2026.

Is Alkem Lab technically bullish or bearish?

As of December 1, 2025, Alkem Lab's technical trend is mildly bullish, supported by bullish weekly MACD and Bollinger Bands, despite mixed signals from monthly indicators.

As of 1 December 2025, the technical trend for Alkem Lab has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The Bollinger Bands are mildly bullish on both weekly and monthly charts, supporting a positive outlook. Daily moving averages are bullish, reinforcing the mildly bullish stance. However, the KST shows a bullish weekly trend but is mildly bearish monthly, and Dow Theory indicates a mildly bearish weekly trend with no clear monthly trend. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands, despite some bearish signals in the monthly indicators.

How has been the historical performance of Alkem Lab?

Alkem Lab has shown consistent growth in net sales and profits, with net sales increasing from 8,344.36 Cr in March 2020 to 12,964.52 Cr in March 2025, and profit after tax rising from 1,149.31 Cr to 2,216.00 Cr during the same period, indicating strong financial performance.

Answer:<BR>The historical performance of Alkem Lab shows a consistent growth trend in net sales and profits over the years, culminating in significant figures for the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Alkem Lab's net sales increased from 8,344.36 Cr in March 2020 to 12,964.52 Cr in March 2025, reflecting a steady upward trajectory. The total operating income followed a similar pattern, rising from 8,344.36 Cr in March 2020 to 12,964.52 Cr in March 2025. The company's operating profit (PBDIT) also saw growth, reaching 3,005.89 Cr in March 2025, up from 1,577.61 Cr in March 2020. Profit before tax increased from 1,259.79 Cr in March 2020 to 2,527.03 Cr in March 2025, while profit after tax rose from 1,149.31 Cr to 2,216.00 Cr over the same period. The earnings per share (EPS) improved significantly from 94.28 in March 2020 to 181.14 in March 2025. On the balance sheet, total assets grew from 9,012.97 Cr in March 2020 to 15,952.85 Cr in March 2025, and total liabilities increased from 9,012.97 Cr to 15,952.85 Cr during the same timeframe. Cash flow from operating activities also showed an upward trend, reaching 1,912.00 Cr in March 2025, although the net cash outflow was recorded at -186.00 Cr. Overall, Alkem Lab has demonstrated robust growth in sales, profits, and assets over the years, indicating a strong financial performance.

Is Alkem Lab overvalued or undervalued?

As of November 13, 2025, Alkem Lab is fairly valued with a PE ratio of 30.06 and solid financial metrics, despite recent stock performance lagging behind the Sensex.

As of 13 November 2025, the valuation grade for Alkem Lab has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 30.06, a Price to Book Value of 5.70, and an EV to EBITDA ratio of 25.45. In comparison to its peers, Sun Pharma has a higher PE ratio of 36.15 and an EV to EBITDA of 23.85, while Cipla is more attractively valued with a PE of 22.65 and an EV to EBITDA of 16.03.<BR><BR>Alkem Lab's financial metrics indicate a solid performance, with a ROCE of 19.77% and a ROE of 18.07%. Despite recent stock performance lagging behind the Sensex over one year (2.53% vs. 8.74%), the company's strong ratios suggest it is positioned well within the pharmaceuticals sector. Overall, Alkem Lab appears to be fairly valued in the current market context.

Who are the top shareholders of the Alkem Lab?

The top shareholders of Alkem Lab include promoters, with Sarandhar Singh holding 19.42%, mutual funds at 14.97%, foreign institutional investors at 9.41%, and individual investors with a combined 15.77%. The largest public shareholder is the ICICI Prudential Multi-Asset Fund, holding 4.11%.

The top shareholders of Alkem Lab include a mix of promoters, mutual funds, and foreign institutional investors (FIIs). The majority shareholders are the promoters, with Sarandhar Singh holding the highest individual stake at 19.42%. Mutual funds collectively hold 14.97% of the shares through 27 different schemes, while FIIs account for 9.41% with 473 different investors. The highest public shareholder is the ICICI Prudential Multi-Asset Fund, which holds 4.11%. Additionally, individual investors have a combined holding of 15.77%.

Has Alkem Lab declared dividend?

Yes, Alkem Laboratories Ltd has declared a dividend of 1850% (₹37 per share), with an ex-date of February 14, 2025. The company has shown varying total returns over different periods, with a notable 110.91% total return over the last 5 years.

Alkem Laboratories Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1850%<BR>- Amount per share: 37<BR>- Ex-date: 14 Feb 25<BR><BR>Dividend Yield: 0.87%.<BR><BR>Total Returns by Period:<BR>Over the last 6 months, the price return was -11.76%, the dividend return was 0.67%, resulting in a total return of -11.09%.<BR><BR>In the 1-year period, the price return was 1.02%, the dividend return was 0.83%, leading to a total return of 1.85%.<BR><BR>For the 2-year period, the price return was 43.8%, the dividend return was 2.56%, which resulted in a total return of 46.36%.<BR><BR>During the 3-year period, the price return was 56.49%, the dividend return was 3.90%, culminating in a total return of 60.39%.<BR><BR>In the 4-year period, the price return was 53.99%, the dividend return was 4.83%, yielding a total return of 58.82%.<BR><BR>Over the last 5 years, the price return was 103.29%, the dividend return was 7.62%, resulting in a total return of 110.91%.<BR><BR>Overall, Alkem Laboratories Ltd has declared a significant dividend, which reflects positively on the company's commitment to returning value to shareholders. The total returns over various periods show a mix of performance, with particularly strong returns over the longer term.